Steven Reichling net worth and biography

Steven Reichling Biography and Net Worth

Steve Reichling has served as the Chief Financial Officer of the company since September 2012. Prior to joining the company, Mr. Reichling served as general manager of Spring Bioscience Corp., a R&D and research products subsidiary of Roche Diagnostics. From January 2003 to December 2009, Mr. Reichling held various finance, accounting and operations leadership roles at Roche Diagnostics and Ventana Medical Systems, Inc., including Director of Finance and Operations, Manager of Business Development Finance, and head of Internal Audit and Sarbanes Oxley Compliance. From October 2002 to January 2003, Mr. Reichling was an auditor at Ernst & Young LLP. Mr. Reichling received his B.A. in accounting and entrepreneurship from the University of Arizona.

What is Steven Reichling's net worth?: The estimated net worth of Steven Reichling is at least $10,962.49 as of March 13th, 2023. Mr. Reichling owns 14,237 shares of Accelerate Diagnostics stock worth more than $10,962 as of April 18th. This net worth estimate does not reflect any other assets that Mr. Reichling may own. Learn More about Steven Reichling's net worth.
How do I contact Steven Reichling?: The corporate mailing address for Mr. Reichling and other Accelerate Diagnostics executives is 3950 South Country Club Suite 470, Tucson AZ, 85714. Accelerate Diagnostics can also be reached via phone at (520) 365-3100 and via email at [email protected]. Learn More on Steven Reichling's contact information.
Has Steven Reichling been buying or selling shares of Accelerate Diagnostics?: Steven Reichling has not been actively trading shares of Accelerate Diagnostics over the course of the past ninety days. Most recently, Steven Reichling sold 470 shares of the business's stock in a transaction on Monday, March 13th. The shares were sold at an average price of $4.90, for a transaction totalling $2,303.00. Following the completion of the sale, the chief financial officer now directly owns 14,237 shares of the company's stock, valued at $69,761.30. Learn More on Steven Reichling's trading history.
Who are Accelerate Diagnostics' active insiders?: Accelerate Diagnostics' insider roster includes Hany Massarany (Director), Jack Phillips (CEO), Ron Price (Insider), Steven Reichling (CFO), and Jack Schuler (Director). Learn More on Accelerate Diagnostics' active insiders.
Are insiders buying or selling shares of Accelerate Diagnostics?: During the last twelve months, insiders at the medical research company sold shares 24 times. They sold a total of 107,388 shares worth more than $145,458.61. The most recent insider tranaction occured on April, 17th when CEO Jack Phillips sold 26,735 shares worth more than $20,853.30. Insiders at Accelerate Diagnostics own 33.0% of the company. Learn More about insider trades at Accelerate Diagnostics.
Information on this page was last updated on 4/17/2024.

Steven Reichling Insider Trading History at Accelerate Diagnostics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2023	Sell	470	$4.90	$2,303.00	14,237
3/8/2023	Sell	6,277	$4.70	$29,501.90	13,764
2/13/2023	Sell	482	$6.00	$2,892.00	7,681
1/13/2023	Sell	473	$6.90	$3,263.70	7,220
8/22/2022	Buy	500	$13.90	$6,950.00	6,749
4/28/2022	Sell	2,991	$9.80	$29,311.80	6,249
5/13/2021	Sell	830	$67.60	$56,108.00	4,297
1/26/2021	Sell	2,491	$125.00	$311,375.00	3,406
11/9/2020	Sell	3,932	$95.00	$373,540.00	5,262
3/19/2020	Buy	100	$64.70	$6,470.00
11/27/2018	Buy	85	$131.30	$11,160.50	230
11/8/2018	Buy	75	$147.20	$11,040.00	145
6/21/2017	Sell	3,000	$289.00	$867,000.00	3,070

Steven Reichling Buying and Selling Activity at Accelerate Diagnostics

Accelerate Diagnostics Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.

Today's Range

Now: $0.77

$0.73

$0.80

50 Day Range

MA: $1.00

$0.74

$1.22

2 Week Range

Now: $0.77

$0.73

$11.90

Volume

34,997 shs

Average Volume

119,337 shs

Market Capitalization

$16.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…